We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bristol-Myers announces $11 billion cancer partnership with BioNTech. CEO Boerner dubs the team up the next new frontier in ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

US factory activity contracted in May for a third consecutive month and a gauge of imports fell to a 16-year low as firms ...

DelveInsight's,“ Advanced Melanoma Pipeline Insight 2025 ” report provides comprehensive insights about 55+ companies and 60+ pipel ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.